Heparin-induced thrombocytopenia and the health economic analysis of argatroban

Br J Anaesth. 2014 Jun;112(6):964-7. doi: 10.1093/bja/aeu011. Epub 2014 Feb 24.

Authors

D A Coventry¹, N R Webster²

Affiliations

¹ Anaesthesia and Intensive Care, University of Aberdeen, Aberdeen, UK.
² Anaesthesia and Intensive Care, University of Aberdeen, Aberdeen, UK Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK n.r.webster@abdn.ac.uk.

PMID: 24569065
DOI: 10.1093/bja/aeu011

No abstract available

Publication types

Editorial

MeSH terms

Arginine / analogs & derivatives
Cost-Benefit Analysis
Drug Costs
Fibrinolytic Agents / adverse effects*
Heparin / adverse effects*
Humans
Pipecolic Acids / economics*
Pipecolic Acids / therapeutic use*
Platelet Aggregation Inhibitors / economics
Platelet Aggregation Inhibitors / therapeutic use*
Sulfonamides
Thrombocytopenia / chemically induced*
Thrombocytopenia / drug therapy*
Thrombocytopenia / economics
United Kingdom

Substances

Fibrinolytic Agents
Pipecolic Acids
Platelet Aggregation Inhibitors
Sulfonamides
Heparin
Arginine
argatroban